Biofrontera annual stock-based compensation
2021
2022
2023
2024
2025
Biofrontera Stock-Based Compensation Growth & History (BFRI)
Biofrontera's stock-based compensation was $951,000 for fiscal 2025.
View full Biofrontera company overviewBiofrontera annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $951,000 | −$68,000 | −6.67% |
| 2024 | 2024-12-31 | $1.0M | −$26,000 | −2.49% |
| 2023 | 2023-12-31 | $1.0M | −$807,000 | −43.57% |
| 2022 | 2022-12-31 | $1.9M | $1.7M | +1335.66% |
| 2021 | 2021-12-31 | $129,000 | — | — |
Biofrontera quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $263,000 | $76,000 | +40.64% |
| Q1 2026 | 2026-03-31 | $342,000 | $103,000 | +43.10% |
| Q4 2025 | 2025-12-31 | $289,000 | −$10,000 | −3.34% |
| Q3 2025 | 2025-09-30 | $236,000 | −$52,000 | −18.06% |
| Q2 2025 | 2025-06-30 | $187,000 | −$17,000 | −8.33% |
| Q1 2025 | 2025-03-31 | $239,000 | $11,000 | +4.82% |
| Q4 2024 | 2024-12-31 | $299,000 | $71,000 | +31.14% |
| Q3 2024 | 2024-09-30 | $288,000 | $81,000 | +39.13% |
| Q2 2024 | 2024-06-30 | $204,000 | −$55,000 | −21.24% |
| Q1 2024 | 2024-03-31 | $228,000 | −$123,000 | −35.04% |
| Q4 2023 | 2023-12-31 | $228,000 | −$155,000 | −40.47% |
| Q3 2023 | 2023-09-30 | $207,000 | −$194,000 | −48.38% |
| Q2 2023 | 2023-06-30 | $259,000 | −$292,000 | −52.99% |
| Q1 2023 | 2023-03-31 | $351,000 | −$166,000 | −32.11% |
| Q4 2022 | 2022-12-31 | $383,000 | — | — |
| Q3 2022 | 2022-09-30 | $401,000 | — | — |
| Q2 2022 | 2022-06-30 | $551,000 | — | — |
| Q1 2022 | 2022-03-31 | $517,000 | — | — |
Biofrontera stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Biofrontera's stock-based compensation increased from $129,000 to $951,000, a change of $822,000. The latest reported quarter, Q2 2026, shows $263,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biofrontera source filings ↗